Oruka Therapeutics, Inc. short interest in 2020
In 2020, Oruka Therapeutics, Inc.'s disclosed short interest ran from 0.27% of shares outstanding on 15 Jan 2020 to 0.44% on 15 Dec 2020, a change of +0.17 percentage points. The year's high was 1.59% on 30 Jun 2020 and its low 0.16% on 28 Feb 2020, averaging 0.83% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.18 days on 15 May 2020. Full history: Oruka Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 0.27% (15 Jan 2020)
- End of year
- 0.44% (15 Dec 2020)
- Change
- +0.17 pp
- High
- 1.59% (30 Jun 2020)
- Low
- 0.16% (28 Feb 2020)
- Average
- 0.83%
- Highest days to cover
- 2.18 (15 May 2020)
- SEC filings marked
- 11
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 0.27% | 1.00 | |
| 31 Jan 2020 | 0.24% | 1.00 | |
| 14 Feb 2020 | 0.38% | 1.00 | |
| 28 Feb 2020 | 0.16% | 1.00 | 10-K filed, results (8-K) |
| 15 May 2020 | 1.43% | 2.18 | 10-Q filed, results (8-K) |
| 15 Jun 2020 | 0.97% | 1.00 | |
| 30 Jun 2020 | 1.59% | 1.00 | |
| 15 Jul 2020 | 1.38% | 1.00 | results (8-K), results (8-K) |
| 31 Jul 2020 | 0.70% | 1.00 | results (8-K) |
| 14 Aug 2020 | 1.49% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2020 | 1.14% | 1.00 | |
| 15 Sep 2020 | 0.92% | 1.00 | |
| 15 Oct 2020 | 1.46% | 1.00 | |
| 30 Oct 2020 | 0.55% | 1.00 | |
| 13 Nov 2020 | 0.45% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2020 | 0.53% | 1.00 | |
| 15 Dec 2020 | 0.44% | 1.00 |
See also: Oruka Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.